Somatropin/mecasermin combination therapeutics - Genentech/Tercica

Drug Profile

Somatropin/mecasermin combination therapeutics - Genentech/Tercica

Alternative Names: Growth hormone/insulin-like growth factor-1; Increlex/NutropinAq; rhGH/rhIGF-1

Latest Information Update: 21 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Tercica
  • Developer Ipsen Biopharmaceuticals; Tercica
  • Class Biological peptides; Growth factors; Growth hormones; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Short stature; Somatotropin deficiency

Most Recent Events

  • 17 Sep 2009 Preliminary safety and efficacy data from a phase II study in children with short stature associated with low level of IGF-1 released by Ipsen
  • 16 Oct 2008 Tercica has been acquired by Ipsen
  • 25 Jan 2008 Phase-II clinical trials in Short stature in children in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top